BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23393050)

  • 1. Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.
    Urtishak KA; Edwards AY; Wang LS; Hudome A; Robinson BW; Barrett JS; Cao K; Cory L; Moore JS; Bantly AD; Yu QC; Chen IM; Atlas SR; Willman CL; Kundu M; Carroll AJ; Heerema NA; Devidas M; Hilden JM; Dreyer ZE; Hunger SP; Reaman GH; Felix CA
    Blood; 2013 Apr; 121(14):2689-703. PubMed ID: 23393050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.
    Driessen EM; van Roon EH; Spijkers-Hagelstein JA; Schneider P; de Lorenzo P; Valsecchi MG; Pieters R; Stam RW
    Haematologica; 2013 Jun; 98(6):937-44. PubMed ID: 23403319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
    Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.
    Jayanthan A; Incoronato A; Singh A; Blackmore C; Bernoux D; Lewis V; Stam R; Whitlock JA; Narendran A
    Pediatr Blood Cancer; 2011 Mar; 56(3):353-60. PubMed ID: 21225911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of genes transcriptionally responsive to the loss of MLL fusions in MLL-rearranged acute lymphoblastic leukemia.
    van der Linden MH; Seslija L; Schneider P; Driessen EM; Castro PG; Stumpel DJ; van Roon E; de Boer J; Williams O; Pieters R; Stam RW
    PLoS One; 2015; 10(3):e0120326. PubMed ID: 25793396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101.
    Spijkers-Hagelstein JA; Schneider P; Pinhanços SM; Garrido Castro P; Pieters R; Stam RW
    Eur J Cancer; 2014 Jun; 50(9):1665-74. PubMed ID: 24703900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MLL-Rearranged Acute Lymphoblastic Leukemia.
    El Chaer F; Keng M; Ballen KK
    Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
    Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
    Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of CD34+ and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia.
    Aoki Y; Watanabe T; Saito Y; Kuroki Y; Hijikata A; Takagi M; Tomizawa D; Eguchi M; Eguchi-Ishimae M; Kaneko A; Ono R; Sato K; Suzuki N; Fujiki S; Koh K; Ishii E; Shultz LD; Ohara O; Mizutani S; Ishikawa F
    Blood; 2015 Feb; 125(6):967-80. PubMed ID: 25538041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia.
    de Groot AP; Saito Y; Kawakami E; Hashimoto M; Aoki Y; Ono R; Ogahara I; Fujiki S; Kaneko A; Sato K; Kajita H; Watanabe T; Takagi M; Tomizawa D; Koh K; Eguchi M; Ishii E; Ohara O; Shultz LD; Mizutani S; Ishikawa F
    EBioMedicine; 2021 Feb; 64():103235. PubMed ID: 33581643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryptic insertion and translocation or nondividing leukemic cells disclosed by FISH analysis in infant acute leukemia with discrepant molecular and cytogenetic findings.
    Watanabe N; Kobayashi H; Ichiji O; Yoshida MA; Kikuta A; Komada Y; Sekine I; Ishida Y; Horiukoshi Y; Tsunematsu Y; Yano M; Nakadate H; Kaneko Y
    Leukemia; 2003 May; 17(5):876-82. PubMed ID: 12750700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biological microchip for establishing the structure of fusion transcripts involving MLL in children with acute leukemia].
    Nasedkina TV; Ikonnikova AY; Tsaur GA; Karateeva AV; Ammour YI; Avdonina MA; Karachunskii AI; Zasedatelev AS
    Mol Biol (Mosk); 2016; 50(6):968-977. PubMed ID: 28064313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
    Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DC; Lock RB
    Blood; 2016 Sep; 128(10):1382-95. PubMed ID: 27343252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype.
    Ramakers-van Woerden NL; Beverloo HB; Veerman AJ; Camitta BM; Loonen AH; van Wering ER; Slater RM; Harbott J; den Boer ML; Ludwig WD; Haas OA; Janka-Schaub GE; Pieters R
    Leukemia; 2004 Mar; 18(3):521-9. PubMed ID: 14712291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL.
    van der Linden MH; Willekes M; van Roon E; Seslija L; Schneider P; Pieters R; Stam RW
    Cell Cycle; 2014; 13(5):834-44. PubMed ID: 24736461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.
    Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.
    Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB
    Clin Cancer Res; 2015 Mar; 21(6):1395-405. PubMed ID: 25573381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
    Stumpel DJ; Schneider P; Pieters R; Stam RW
    Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device.
    Harrison CJ; Griffiths M; Moorman F; Schnittger S; Cayuela JM; Shurtleff S; Gottardi E; Mitterbauer G; Colomer D; Delabesse E; Castéras V; Maroc N
    Cancer Genet Cytogenet; 2007 Feb; 173(1):17-22. PubMed ID: 17284365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia.
    Mousavian Z; Nowzari-Dalini A; Stam RW; Rahmatallah Y; Masoudi-Nejad A
    Cell Oncol (Dordr); 2017 Feb; 40(1):33-45. PubMed ID: 27798768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.